| Name | Title | Contact Details |
|---|
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.
RareCyte is a company focused on characterizing and isolating rare cells from blood.
bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
Reprocell is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.